2020
Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease
Weintraub D, Caspell‐Garcia C, Simuni T, Cho HR, Coffey CS, Aarsland D, Alcalay RN, Barrett MJ, Chahine LM, Eberling J, Espay AJ, Hamilton J, Hawkins KA, Leverenz J, Litvan I, Richard I, Rosenthal LS, Siderowf A, York M, Initiative P. Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. Annals Of Clinical And Translational Neurology 2020, 7: 449-461. PMID: 32285645, PMCID: PMC7187707, DOI: 10.1002/acn3.51022.Peer-Reviewed Original ResearchConceptsParkinson's disease participantsNeuropsychiatric symptomsParkinson's diseaseHealthy controlsCognitive impairmentMedication useYear 5Anticholinergic medication useCross-sectional prevalenceParkinson's disease patientsHypnotic useDisease patientsNeuropsychiatric featuresDisease onsetAnnual visitsSymptomsDisorder subtypesAbsolute prevalenceDiseaseTime pointsPrevalenceBaselineImpairmentParticipantsOnset
2003
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis I. Study rationale and design
McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, Hawkins KA, Hoffman R, Lindborg S, Tohen M, Breier A. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis I. Study rationale and design. Schizophrenia Research 2003, 61: 7-18. PMID: 12648731, DOI: 10.1016/s0920-9964(02)00439-5.Peer-Reviewed Original ResearchConceptsPsychosis onsetClinical trialsDouble-blind placebo-controlled clinical trialStudy rationaleDouble-blind clinical trialPlacebo-controlled clinical trialAtypical neuroleptic medicationsNew diagnostic criteriaClinical trial designPutative prodromal syndromeTreatment-seeking patientsOngoing symptomatologyNeuroleptic medicationHigh riskDiagnostic criteriaTrial designEarly courseProdromal SyndromesClinical phenomenologyStudy designClinical populationsPatientsOnsetIntervention researchTrials